ライフサイエンスコーパス: infected patient

1 is isolate with the clinical outcome for the infected patient.

2 and never analyzed in the circulation of HIV-infected patients.

3 on and can be a way to prevent HIV spread in infected patients.

4 e lamina propria of seronegative acutely HIV-infected patients.

5 he daily functioning and independence of HIV-infected patients.

6 apeutic treatment is available to treat ZIKV-infected patients.

7 al infection and a high mortality rate among infected patients.

8 to establish control of HIV-1 replication in infected patients.

9 tems, as well as in clinical trials in HIV-1-infected patients.

10 of both M1 and M2 macrophages in chronic HCV infected patients.

11 od samples were taken from 100 confirmed HIV infected patients.

12 in liver biopsy samples from chronically HCV-infected patients.

13 bodies against HCV isolated from chronically infected patients.

14 nd enhances care linkage for chronically HCV-infected patients.

15 al response (SVR) in hepatitis C virus (HCV)-infected patients.

16 ection because of latent viral reservoirs in infected patients.

17 nsight into residual viremia dynamics in HIV-infected patients.

18 culture of CD4+ T-cells obtained from HIV-1 infected patients.

19 e higher prevalence of hypertension in HIV-1-infected patients.

20 chronic illness may improve survival in HIV-infected patients.

21 iated with increased incidence of NHL in HIV-infected patients.

22 der (HAND) affects approximately half of HIV-infected patients.

23 activation and expansion in untreated HIV-1-infected patients.

24 Its diagnosis is thus vital for HBV-infected patients.

25 analyze integration sites in cells from HIV-infected patients.

26 mployed to improve clinical outcomes for RSV-infected patients.

27 additional TDF-related renal toxicity in HIV-infected patients.

28 ound improvement in the clinical care of HIV-infected patients.

29 cted CD8(+) T cells can be found in some HIV-infected patients.

30 t cancer, cholangiocarcinoma, in chronically infected patients.

31 iated with increased incidence of NHL in HIV-infected patients.

32 mily Filoviridae and cause high lethality in infected patients.

33 iagnosis and management of these chronically infected patients.

34 der (HAND) affects approximately half of HIV-infected patients.

35 ading to suppression of Tfh responses in HCV-infected patients.

36 xacerbated neurocognitive dysfunction in HIV-infected patients.

37 CD39(+) Treg cells in the circulation of HIV-infected patients.

38 and tolerability in hepatitis C virus (HCV)-infected patients.

39 cal alteration and cytotoxic activity in HIV-infected patients.

40 litate transmission, and thwart treatment of infected patients.

41 n seminal plasma (SP) of treatment-naive HIV-infected patients.

42 eline, L159F was detected only in genotype 1-infected patients (1%) and was only associated with incr

43 We identified 21,095 hepatitis C virus-infected patients (11,029 [52%] white, 6,171 [29%] black

44 2 HIV-infected patients (16%) and 32 non-HIV-infected patients (14%), with a probability of 4% versus

45 Of the 301 chronically infected patients, 158 had follow-up arranged (52%), of

46 HCC recurred in 12 HIV-infected patients (16%) and 32 non-HIV-infected patients

47 Of 119 suspected ZIKV-infected patients, 25 (21%) were confirmed by RT-PCR of

48 ies and phenotypes were determined in 49 HDV-infected patients, 25 individuals with hepatitis B virus

49 Fifteen infected patients (26.8%) were symptomatic.

50 ed (73%; 95% CI, 50% to 89%): nine of 15 HIV-infected patients (60%; 95% CI, 32% to 84%) and all seve

51 y HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV la

52 Many providers had counseled HIV-infected patients about PrEP for partners (59.0%) or off

53 ed phenotypes of immune activation among HIV-infected patients across a spectrum from malnutrition to

54 h sleep disturbance in a large cohort of HIV-infected patients across China.

55 All blood samples from suspected Ebola virus-infected patients admitted to the Medecins Sans Frontier

56 ), long-term nonprogressors (n = 7), and HIV-infected patients affected by tumor (n = 4).

57 Nasal wash samples from influenza-infected patients also showed increased accumulation of

58 Liver retransplantation is performed in HIV-infected patients, although its outcome is not well know

59 antly among IgM(+) memory B cells of all HCV-infected patients analyzed.

60 ripheral blood B cells of 30 MC-negative HCV-infected patients and 15 healthy controls revealed that

61 In a cohort of 56,448 HCV-infected patients and 169,344 propensity score (1:3)-mat

62 Seventy-four HIV-infected patients and 222 non-HIV-infected patients were

63 tter microstructure were assessed in 134 HIV-infected patients and 79 controls.

64 n in Florida by sequencing ZIKV genomes from infected patients and Aedes aegypti mosquitoes.

65 d TRAILshort, a TRAIL splice variant, in HIV-infected patients and characterized it as being a domina

66 e major iNOS(+) cell population in H. pylori-infected patients and confirmed intracellular NO product

67 Outcomes between HIV-infected patients and controls were not statistically si

68 e cloned multiple Env sequences from 7 HIV-2-infected patients and found that about half were able to

69 e the expression of clag3 genes in naturally infected patients and in experimentally infected human v

70 itor 1 (PAI-1), in Puumala hantavirus (PUUV)-infected patients and in human microvascular endothelial

71 st care provider for hepatitis C virus (HCV)-infected patients and is uniquely suited to inform natio

72 ls and low progression rates (vertically HIV-infected patients and LTNPs, including HIV controllers)

73 human immunodeficiency virus infection (HIV)-infected patients and preexposure prophylaxis (PrEP) as

74 sion of HCV viral proteins in B cells of HCV-infected patients and show that HCV upregulates BCR sign

75 dicts disease progression in untreated HIV-1-infected patients and suggests that elevated IL-15 may a

76 ase (CKD) in chronic hepatitis C virus (HCV)-infected patients and the incidence reduction of CKD aft

77 In the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs pra

78 eg) gammadelta T cells was monitored in each infected patient, and the expansion rate during this pha

79 CV) establishes persistent infection in most infected patients, and eventually causes chronic hepatit

80 nce of venous thromboembolism is 1.5-3.4% of infected patients, and it occurs due to a hypercoagulabl

81 e mediators were specifically higher in ZIKV-infected patients, and levels of interleukin 10, interfe

82 olonized and/or infected) and the outcome of infected patients, and monitored the environmental occur

83 rns have been raised that risks of KT in HIV-infected patients are higher than those in their HIV-neg

84 or both HIV co-infected and hepatitis C mono-infected patients are suggested.

85 screening venues where 2%-10% of chronically infected patients are treated.

86 Thus, our results demonstrate that infected patients associated with USA300 either as an in

87 of naturally-occurring dengue NS1 antigen in infected patient blood plasma using straight long-range

88 1) protein of the dengue virus circulates in infected patients' blood samples and can be used for ear

89 n a sample of predominantly male, black, HIV-infected patients but was insufficient to overcome adjus

90 olateral wall, was prevalent in 82.1% of HIV-infected patients, but only in 27.3% of healthy controls

91 el persistent viral shedding in the urine of infected patients, but the associated mechanisms have no

92 rdiovascular involvement in asymptomatic HIV-infected patients by a comprehensive cardiac magnetic re

93 clinical trials of chemotherapy because most infected patients can achieve virologic cure.

94 ency in various HIV-1 latency models and HIV-infected patient cells.

95 Human immunodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and

96 ce and determinants of hypertension in HIV-1-infected patients compared with appropriate HIV-negative

97 of the brain stem was reduced in all HTLV-1-infected patients compared with controls (P < 0.001), wh

98 as emerged as a viable option for select HIV-infected patients, concerns have been raised that risks

99 leukocytes, biopsy specimens from H. pylori-infected patients, controls, and participants of a vacci

100 ession in the lymph nodes of untreated HIV-1-infected patients correlated with circulating CD8+ T cel

101 Overall, 36298 HIV-infected patients covered by commercial payers, 26246 co

102 equent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these pati

103 Human immunodeficiency virus (HIV)-infected patients demonstrate increased activation of th

104 It is not clear why some HIV-1-infected patients develop HAND, despite effective repres

105 ortion of human immunodeficiency virus (HIV)-infected patients develop persistent, stigmatizing human

106 cute and early convalescent phases from ZIKV-infected patients during the Singapore outbreak in Augus

107 In dengue-infected patients, elevated levels of syndecan-1 and cho

108 addition, both sera and mAbs from the dengue-infected patients enhanced ZIKV infection of Fc gamma re

109 Retrospective chart review of HIV-infected patients enrolled in a large, urban clinic in 2

110 remain in the clinical management of dengue-infected patients, especially in the absence of reliable

111 inely assessing sleep disturbances among HIV-infected patients, especially in the first three months

112 Many HIV-1-infected patients evolve broadly neutralizing antibodies

113 troviral therapy (cART), the majority of HIV-infected patients exhibit persistent seropositivity to H

114 In addition, HCV-infected patients experienced a twofold and a nearly 17-

115 ZIKAV could persist in the tears of infected patients for up to 30 days post-illness, and ma

116 ART-naive HIV-1-infected patients from Cameroon were subjected to a mult

117 arch databases were used to select adult HIV-infected patients from each payer.

118 ing characteristic curves for discriminating infected patients from healthy controls for the Sepsis M

119 nt success and disease in 97 L. braziliensis-infected patients from Peru and Bolivia.

120 rt study with 834 Mycobacterium tuberculosis-infected patients from selected hospitals and clinics wi

121 Infected patients generate VH3 plasmablast expansions an

122 ling of human genes from the same sputa, HIV-infected patients had 3.4-fold lower expression of IFNG

123 riate time-varying Cox regression model, HCV-infected patients had a 27% increased risk of CKD compar

124 NTM-infected patients had at least 1 positive culture for NT

125 Infected patients had higher risk for death (18 vs. 8 de

126 HIV-infected patients had increased circulating levels of fu

127 M. tuberculosis in HIV-infected patients had lower expression of the DosR regul

128 Estimates suggest that only 20 % of HCV-infected patients have been identified and <10 % treated

129 826-like sequences can be identified in H7N9-infected patients, healthy adults, and newborn babies.

130 rin for 12 or 24 weeks in HCV genotype (GT)1-infected patients, high rates of sustained virologic res

131 ecognized as an important comorbidity of HIV-infected patients, however, the exact molecular mechanis

132 This assay was then used to screen all HBV-infected patients identified in a large randomly selecte

133 ed 30 potentially Chlamydia trachomatis (CT)-infected patients in a hospital emergency department and

134 Is) among human immunodeficiency virus (HIV)-infected patients in care in the United States and Canad

135 (representative of Italian hepatitis C virus-infected patients in care).

136 IV-1 penetration in mucosa or in chronically infected patients in combination with antiretroviral the

137 whether DAA antiviral treatment of DLBCL/HCV-infected patients in concomitance with chemotherapy is a

138 been isolated in pulmonary samples from NTM-infected patients in the region.

139 s spectrometry in plasma samples from 32 HIV-infected patients in whom active tuberculosis developed

140 ancers in human immunodeficiency virus (HIV)-infected patients in Zambia.

141 athogenesis of comorbidities observed in HIV-infected patients, including those with virologic suppre

142 In HIV-1-infected patients, increased numbers of circulating CD8+

143 t this peptide were detected in DV naturally infected patients indicating its potential antigenicity.

144 Matrix turnover in HIV-1-infected patients is increased before and during TB-IRIS

145 hematopoietic cell transplant (AHCT) for HIV-infected patients is largely limited to centers with HIV

146 s C virus (HCV) infection promote NHL in HIV-infected patients is unclear.

147 In Zika-infected patients, levels of IL-1beta showed a significa

148 BBB-associated neuropathogenesis in HIV-infected patients may initiate during primary infection.

149 type analyses in a cohort of HIV-1 subtype C-infected patients (n = 168), together with site-directed

150 ents with cancer (n = 53), hepatitis C virus-infected patients (n = 17), and healthy donors (n = 173)

151 pendent replication cohort of HCV genotype 1-infected patients (n = 201).

152 ized trial of behavioral weight loss for HIV-infected patients (n = 40).

153 myocardial inflammation were elevated in HIV-infected patients (native T1 relaxation times, 1128.3+/-

154 ary to the hypothesis formulated, PBMCs from infected patients obtained at the time of infection disp

155 HIV-infected patients of all ages frequently underperform in

156 he HIV reservoir in a single chronically HIV-infected patient on suppressive antiretroviral therapy w

157 ross-sectional study was conducted among HIV-infected patients on antiretroviral therapy at 20 AIDS c

158 emains, below the level of detection, in HIV-infected patients on ART.

159 HIV-infected patients on EFV plus tenofovir/emtricitabine or

160 ls accumulate in the blood of aviremic HIV-1-infected patients on long-term antiretroviral therapy, a

161 ately 1 in 10(6) cells and in cells from HIV-infected patients on suppressive antiretroviral therapy

162 In 44.6% of HCV genotype 1-infected patients, only the variant rs12785878 in the DH

163 10 (IL-10) level in serum specimens from HSV-infected patients (P= .007) and CSF specimens from all p

164 A total of 103 dengue-infected patients participated in the study.

165 le and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassion

166 e intrahepatic distribution of HBV cccDNA in infected patients, particularly at the single-cell level

167 C-infected, and human immunodeficiency virus-infected patients per the transplant center protocol.

168 Twenty primary HCMV-infected patients (PHIP) were enrolled, as well as 26 HC

169 etion during HIV infection.IMPORTANCE In HIV-infected patients, progressive CD4(+) T cell loss ultima

170 trate that human transcription signatures in infected patients recapitulate the underlying biology an

171 mptomatic human immunodeficiency virus (HIV)-infected patients receiving antiretroviral therapy.

172 Conclusion: In HIV-infected patients receiving ART, chronic co-infection wi

173 In HIV-infected patients receiving ART, chronic co-infection wi

174 HCV-infected patients receiving cancer treatment at our inst

175 HCV reactivation occurred in 23% of HCV-infected patients receiving cancer treatment, and most h

176 vir (DTG) concentrations in the semen of HIV-infected patients receiving DTG-based first-line therapy

177 ogeneity in the disease progression of HIV-1-infected patients receiving long-term antiretroviral the

178 conducted among human immunodeficiency virus-infected patients receiving lopinavir/ritonavir-based re

179 and prior null-responder HCV genotype (GT) 1-infected patients receiving simeprevir+sofosbuvir+/-riba

180 Moreover, colonization with USA300 in infected patients, regardless of their infecting strain,

181 fferent anatomical compartments from 20 HCMV-infected patients (renal transplant recipients, stem cel

182 HIV-infected patients requiring HCT may also be considered f

183 using sera from GII.4 and the GII.17 variant-infected patients, respectively, we observed limited cro

184 SVR rates of 93% and 100% in GT1a- and GT1b-infected patients, respectively, were achieved in this s

185 Chronically HCV-infected patient sera inhibited C3 convertase activity,

186 should not contraindicate cancer therapy and infected patients should have access to multiple cancer

187 An ophthalmologic follow-up for Ebola-infected patients should start, if possible, during the

188 tionality, under unstimulated conditions HIV-infected patients showed a higher percentage of classica

189 HIV-infected patients showed a more activated phenotype of m

190 When compared with healthy controls, HIV-infected patients showed alterations in left ventricular

191 blood mononuclear cells isolated from CHIKV-infected patients showed elevated NLRP3, caspase-1 and i

192 for experimental testing.IMPORTANCE Many HIV-infected patients slowly evolve antibodies that can neut

193 riological status at diagnosis among 127 HIV-infected patients starting TB treatment.

194 ailable for therapeutic intervention for AIV-infected patients, studies on NAI resistance among AIVs

195 CD4(+) T-cell counts/percentages in 93 HIV-1-infected patients subdivided as follows: naive (n = 63),

196 Of the 80 infected patients, test results for 74 (93%) would have

197 sponse to TLR agonists was greater among HIV-infected patients than among control subjects.

198 to sialostatin L2 in sera from 21 out of 23 infected patients than in sera from control individuals

199 cytes, may have clinical implications in HIV-infected patients that are different from those in aging

200 es can be detected in the lungs and blood of infected patients, the role of extra-respiratory organs

201 In HIV-infected patients, the sensitivity of a single SMF was 6

202 43.4%, P = 0.03), but in HCV non-genotype 1-infected patients, the SVR rate did not differ between t

203 iSNVs) from deep-sequenced samples from EBOV-infected patients, through a well-tailored bioinformatic

204 re performed between 2003 and 2013 among HIV-infected patients to quantify the proportion with indivi

205 Staphylococcus aureus-infected patients treated with antibiotics that are effe

206 Among genotype 1-infected patients treated with ledipasvir/sofosbuvir mon

207 rence of peculiar lymphoma histotypes in HIV-infected patients under cART.

208 he occurrence of ocular complications in HIV infected patients undergoing antiretroviral therapy at t

209 prospective Spanish nationwide cohort of HIV-infected patients undergoing LT for HCC (2002-2014).

210 uals, in addition to a cohort of chronically infected patients undergoing ribavirin therapy.

211 n different organs and tissues even in HIV-1-infected patients undergoing successful combined antiret

212 ncentrations on sputum samples obtained from infected patients (up to 100 muM).

213 In P. falciparum-infected patients, Vgamma9Vdelta2 T cells presented incr

214 outcome in laboratory-confirmed Ebola virus-infected patients was analyzed as a function of age, sex

215 nocytes isolated from ZIKV- and dengue virus-infected patients was comparable, except for significant

216 stosoma eggs or miracidia recovered from the infected patients was conducted to elucidate the epidemi

217 g cells in the lamina propria of acutely HIV-infected patients was positively associated with biomark

218 feature in clinical chemistry of Ebola virus-infected patients was the elevation in alanine aminotran

219 Using samples derived from HIV-infected patients, we demonstrate that, although IA in b

220 characterizing memory lymphocytes from ZIKV-infected patients, we dissected ZIKV-specific and DENV-c

221 In vivo, in chronic HCV-infected patients, we found increased expression of TLR7

222 Ebola virus-infected patients were 20% more likely to survive when P

223 chronically HCV-infected and chronically HCV-infected patients were 60.2 and 194.3 per 100,000 person

224 Sera from suspected ZIKV-infected patients were analyzed for viral RNA and antibo

225 Two-hundred seventeen O. viverrini-infected patients were assigned to the 5 treatment arms.

226 The remaining NTM infected patients were classified as colonized.

227 Phenotypic susceptibility calls from 8 HIV-1 infected patients were consistent with 80-90% genotypic

228 For decades, HIV-infected patients were excluded from consideration for k

229 A total of 721 HIV-infected patients were included (76.3% were male; median

230 y-four HIV-infected patients and 222 non-HIV-infected patients were included.

231 Treated HIV-infected patients were matched to HIV-negative controls.

232 HCV genotype 3-infected patients were more likely to progress to cirrho

233 A total of 200 Helicobacter pylori infected patients were retrospectively included (female

234 HIV-infected patients were significantly less accurate on th

235 HIV-infected patients were successfully controlled for the d

236 arbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibacta

237 HCV genotype 1-infected patients were vaccinated using heterologous ade

238 Whereas 31 (9.2%; 18 colonized, 13 infected) patients were affected in 2012 and 2013, the n

239 a high baseline viral load in HCV genotype 1-infected patients, which may explain a lack of correlati

240 stent plasma viremia during cART in an HIV-1-infected patient who had squamous cell cancer.

241 HIV-infected patients who are healthy and have low risk of A

242 f tracing human immunodeficiency virus (HIV)-infected patients who are lost to follow-up (LTFU) on re

243 e considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have c

244 ategy for hepatitis C virus (HCV) genotype 1-infected patients who fail direct-acting antiviral (DAA)

245 ed substitutions identified in NS3 from GT1a-infected patients who failed therapy with grazoprevir (i

246 onducted in 302 human immunodeficiency virus-infected patients who had a CD4 T-cell count <100 cells/

247 leukin 1beta (IL-1beta) were lower in dengue-infected patients who had experienced a previous dengue

248 of allogeneic HCT (alloHCT) in selected HIV-infected patients who meet standard transplant criteria.

249 HCV treatment was highly effective among HIV-infected patients who received care within an integrated

250 Twenty-three GT1-infected patients who relapsed following initial treatme

251 HCV-infected patients who underwent at least 2 liver biopsie

252 d tumorigenesis, which helps explain why HIV-infected patients, who frequently suffer from opportunis

253 e immune function and life expectancy in HIV-infected patients whose respiratory allergic incidence i

254 About 30% of infected patients will develop chronic Chagas cardiomyop

255 KT may provide survival benefit for the HIV-infected patient with ESRD, yet this important clinical

256 d samples from hemorrhagic fever virus (HFV)-infected patients with 0.1% detergents has been recommen

257 nsitivity of urinary LAM is increased in HIV-infected patients with a CD4 </= 100 cells/mm(3).

258 ex, and CD4 cell count, and 37 unmatched HIV-infected patients with a diagnosis of pneumonia.

259 ted within a prospective cohort study of HIV-infected patients with active pulmonary tuberculosis and

260 or treatment-experienced (n = 37) genotype 3-infected patients with advanced fibrosis (n = 14) or com

261 Among HIV-infected patients with advanced immunosuppression, enhan

262 12 or 16 weeks of treatment among genotype 3-infected patients with advanced liver disease, irrespect

263 E), among human immunodeficiency virus (HIV)-infected patients with and without hepatitis B virus (HB

264 and access to effective therapeutics for HIV-infected patients with cancer and make studies more gene

265 without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly.

266 ayelitsha, South Africa, in hospitalized HIV-infected patients with CD4 cell counts <350/microL and m

267 Hepatitis C virus (HCV)-infected patients with chronic kidney disease (CKD) have

268 Hepatitis C virus (HCV)-infected patients with cirrhosis are historically a diff

269 -sofosbuvir (SOF) in treating HCV genotype-4 infected patients with cirrhosis or postliver transplant

270 and 80% (16 of 20) and 81% (17 of 21) in GT1-infected patients with cirrhosis treated for 6 and 8 wee

271 SVR12 in GT3-infected patients with cirrhosis was 83% (10 of 12) afte

272 rhagic stroke, and new-onset dialysis in HCV-infected patients with CKD.

273 th or without ribavirin (RBV) in GT1- or GT3-infected patients with compensated cirrhosis.

274 s all payers, the proportions of treated HIV-infected patients with deep vein thrombosis, hepatitis C

275 ) results among human immunodeficiency virus-infected patients with disseminated nontuberculous mycob

276 ecommendation of a single dose of BPG in HIV-infected patients with early syphilis.

277 Selected human immunodeficiency virus (HIV)-infected patients with end organ failure can safely rece

278 tation in human immunodeficiency virus (HIV)-infected patients with end-stage renal disease (ESRD).

279 nsplantation is an acceptable option for HIV-infected patients with HBV or HCV coinfection but undete

280 results support the indication of LT in HIV-infected patients with HCC.

281 his study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusin

282 wn to be safe and effective for selected HIV-infected patients with hematological malignancies.

283 e difference in GU healing between H. pylori-infected patients with IM and those without IM.

284 HIV-infected patients with information on HBV surface antige

285 Patients: HIV-infected patients with information on HBV surface antige

286 nvolving the simultaneous treatment of HIV-1-infected patients with latency-reversing agents (LRAs) a

287 t mutation that arises from treatment of HIV-infected patients with nevirapine, the first-in-class dr

288 egravir (RAL) on hepatic steatosis among HIV-infected patients with nonalcoholic fatty liver disease

289 1163 Staphylococcus aureus genomes from 105 infected patients with nose colonization.

290 (PIB) +/- ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DA

291 ortion of human immunodeficiency virus (HIV)-infected patients with specific comorbidities receiving

292 dinal whole-blood microarray analysis of HIV-infected patients with TBM and reflected the findings at

293 The identification of HIV-1-infected patients with these activities within the first

294 n genes were less highly expressed among HIV-infected patients with tuberculosis than among HIV-uninf

295 infected individuals as compared to acutely infected patients, with high sensitivity and specificity

296 mal difference in either outcome between HIV-infected patients without a history of AIDS and uninfect

297 Ambulatory HIV-infected patients without active tuberculosis were recru

298 Similar to the optimal therapy for HCV-infected patients without cancer, the optimal therapy fo

299 Among GT3-infected patients without cirrhosis, SVR12 was 93% (14 o

300 Reduced CD4 monitoring of HIV-infected patients would result in modest cost savings an